Imeik Technology Development Co

Imeik Technology Development Co EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co (300896.SZ) as of Oct 17, 2026 is 14.77 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was 27.46 % — a change of -46.21% (lower).

EBIT/Assets

14.77 %

YoY

-46.21%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co is 2025 14.77 % . Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co was 2024 27.46 % . It decreases by -46.21% lower compared to the previous year.

The Imeik Technology Development Co EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
30.90 CNY
Jan 1, 2019
47.09 CNY
Jan 1, 2020
10.76 CNY
Jan 1, 2021
21.37 CNY
Jan 1, 2022
23.78 CNY
Jan 1, 2023
31.50 CNY
Jan 1, 2024
27.46 CNY
Jan 1, 2025
14.77 CNY
The Imeik Technology Development Co EBIT/Assets history
YEAREBIT/AssetsYoY
14.77 %-46.21%
27.46 %-12.81%
31.50 %+32.45%
23.78 %+11.27%
21.37 %+98.58%
10.76 %-77.15%
47.09 %+52.40%
30.90 %+30.74%
23.64 %+19.64%
19.76 %+25.48%
15.74 %-49.88%
31.41 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Imeik Technology Development Co Stock analysis

What does Imeik Technology Development Co do? Imeik Technology Development Co Ltd is a biotechnology company based in Beijing, China, operating within the healthcare sector. The company focuses on the research, development, and industrialization of biomedical materials, particularly recombinant proteins and peptides. It has established a product technology transformation platform for biomedical materials, including medical chitosan and polylactic acid. Imeik has successfully industrialized injection-type sodium hyaluronate series products and polydioxanone facial implants. Its self-developed products are primarily designed for the repair of facial and neck skin folds, with clinical applications spanning medical cosmetology, surgical repair, and the treatment of metabolic diseases. The company went public on the Shenzhen Stock Exchange on September 28, 2020, with ticker 300896.SZ and ISIN CNE100004868. Imeik currently employs 713 full-time staff and operates exclusively within the Chinese market. Its website is www.imeik.net, providing information on its products and services. The company emphasizes the development and transformation of biomedical materials, aiming to advance biomedicine through its specialized focus on recombinant proteins and peptides. It has developed a range of products that address specific medical and cosmetic needs, contributing to its position in the healthcare industry. Imeik Technology Development Co is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Imeik Technology Development Co stock

Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co is 14.77 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Imeik Technology Development Co changed from 27.46 % to 14.77 %, representing a -46.21% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Imeik Technology Development Co since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Imeik Technology Development Co with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Imeik Technology Development Co

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Imeik Technology Development Co